Roche Holding Ltd · SIX:RO
Roche — Investor Presentation (2020)
41 slides from Roche's investor presentation, 2020
Slide 1: Roche Diagnostics Introduction and Business Overview
Roche Diagnostics Introduction and Business Overview
Slide 2: About Roche Diagnostics
About Roche Diagnostics Diagnostics Strategy and Business Model Financials Organization and Core Technologies Personalized Healthcare and Data Management 2
Slide 3: Roche Clear Leader in Growing IVD Market
Roche Clear Leader in Growing IVD Market Share of IVD sales 2018 Expected IVD market growth IVD Market: CHF 61bn CHF 78bn +5% CAGR Tissue Diagnostics +7% CAGR Molecular Diagnostics +10% CAGR 19% Blood Glucose Monitoring -4% CAGR Tissue Diagnostics Molecular Diagnostics Blood Glucose Monitoring 12% 9
Slide 4: Diagnostics in a Glance
Diagnostics in a Glance Diagnostics Division as Part of Roche Group Diagnostics Division 21% of 2019 Revenue % of Group Core Operating Profit % of Group R&D spend 9% 13% 4
Slide 5: About Roche Diagnostics
About Roche Diagnostics Diagnostics Strategy and Business Model Financials Organization and Core Technologies Personalized Healthcare and Data Management 5
Slide 6: Our competitive advantage
Roche Diagnostics Our competitive advantage Total solution offering Breadth of technologies Comprehensive menu IT and workflow connectivity End-to-end workflow 6
Slide 7: Servicing Clinical Diagnostics Customers
Servicing Clinical Diagnostics Customers Managing complex product offering and business processes Roche Diagnostics Customers Central lab Pathology Patients (Self Testing) Molecular Lab Point of Care Roche Diagnostics Business Model 7
Slide 8: Financials
About Roche Diagnostics Diagnostics Strategy and Business Model Financials Organization and Core Technologies Personalized Healthcare and Data Management 8
Slide 9: 2019: Diagnostics Division sales
2019: Diagnostics Division sales Growth driven by Centralised and Point of Care Solutions and Molecular Diagnostics 2019 2018 Change in % CHFm CHFm CHF CER Diagnostics Division 12,950 12,879 1 3 Centralised and Point of Care Solutions 7,819 7,768 1 3 Molecular Diagnostics 2,109 2,019 4 6 Diabetes Ca
Slide 10: 2019: Diagnostics Division regional sales
2019: Diagnostics Division regional sales Growth driven by Asia Pacific and Latin America Japan North America -2% 0% EMEA1 ~4% of divisional sales ~25% of divisional sales +2% ~38% of divisional sales Asia Pacific Latin America +6% +12% ~27% of divisional sales ~7% of divisional sales +7% growth in
Slide 11: 2019: Diagnostics Division highlights
2019: Diagnostics Division highlights Growth driven by immunodiagnostics YoY CER growth Centralised and Point • Immunodiagnostics (+6%; reagents +8%) +3% of Care • Decline in coagulation monitoring Solutions Molecular • Blood screening (+7%); Point of Care 1 +6% Diagnostics molecular diagnostics (+3
Slide 12: 2019: Diagnostics Division core operating profit
2019: Diagnostics Division Core operating profit growing at +1% 2019 2019 vs. 2018 CHFm % sales CER growth Sales 12,950 100.0 3% 6% Royalties & other op. inc. 87 0.7 6% Cost of sales -6,183 -47.8 6% M&D -2,909 -22.5 0% R&D -1,468 -11.3 1% G&A -511 -3.9 -2% -2% Core operating profit 1,966 15.2 1% -4%
Slide 13: Organization and Core Technologies
About Roche Diagnostics Diagnostics Strategy and Business Model Financials Organization and Core Technologies Personalized Healthcare and Data Management 13
Slide 14: Our Business Area/Unit structure
Our Business Area/Unit structure Centralized and POC Molecular Solutions Solutions • Serum work area/immuno-assays and Molecular Diagnostics Tissue Diagnostics Sequencing Unit clinical chemistry • Virology • Primary staining • Sample preparation • Point-of-care testing • Blood screening • Advanced s
Slide 15: Integrated Core Lab
Integrated Core Lab Expansion with additional solutions and entering new disciplines Digital Solutions Consulting Viewics Service Roche Healthcare Consulting Integrating Disciplines Remote Service Lab Molecular Coagulation Lab Software cobas 6800/8800 cobas t 511/711 Automation cobas infinity Assays
Slide 16: Centralized and Point of Care Solutions
About Roche Diagnostics Diagnostics Strategy and Business Model Financials Organization and Core Technologies – Centralized and Point of Care Solutions Personalized Healthcare and Data Management 16
Slide 17: Our strategic roadmap
Centralised and Point of Care Solutions Our strategic roadmap Yesterday Today 2022 Best in Integrated Core + Integrated diagnostic Best in Serum Work Area information anywhere, anytime Laboratory We shaped the market by Integrating further disciplines Making diagnostic information connecting clinica
Slide 18: #1 in clinical chemistry and immunoassays
Centralised and Point of Care Solutions #1 in clinical chemistry and immunoassays New launches of Immunoassays PIVKA-II EBV VCA IgG IGFBP-3 EBV IgM FT4 III Androstenedione Anti-HAV II Lyme IgG Anti-p53 Lyme IgM cobas c 503 analytical unit cobas e 801 analytical unit EBV EBNA IgG AFP-L3, GALAD Score
Slide 19: Launch of cobas mobile solutions
Launch of cobas® mobile solutions Digital tool designed to boost laboratory efficiency and convenience Enables direct monitoring and interaction with serum work area systems through a platform of apps available on a tablet cobas cobas screen User Roche cobas app mobicheck share Assistance DiaLog zon
Slide 20: Other lab instruments
Other lab instruments Portfolio Overview cobas c 513 cobas t 511 cobas t 711 cobas 6500 analyzer Diabetes Core Lab Urine Testing Testing Coagulation • HbA1c (Glycated • Blood coagulation • Fully automated hemoglobin) management urine work area analyzer solution HbA1c = Hemoglobin A1c 20
Slide 21: Comprehensive menu that continues to grow
Comprehensive menu that continues to grow We develop medical value assays that change patients’ lives Disease Infectious Oncology Cardiovascular Neurology Women’s health Others Area ~350 ~35 Diseases ~35 3 ~20 ~390 No. of tests Major Implementation of Fastest time to Plasma Separation FDA break- NIC
Slide 22: POC testing solutions
POC testing solutions Portfolio overview Accu-Chek cobas b123 CoaguChek Pro Urisys 1100 cobas h232 cobas b101 Inform II / CoaguChek INRange Glucose Blood gas & Coagulation Urinalysis Cardiac HbA1C, Lipids Electrolytes and CRP HbA1c = Hemoglobin A1c; CRP = C-reactive protein 22
Slide 23: Molecular Diagnostics
About Roche Diagnostics Diagnostics Strategy and Business Model Financials Organization and Core Technologies – Molecular Diagnostics Personalized Healthcare and Data Management 23
Slide 24: Roche Molecular Solutions
Roche Molecular Solutions Connecting complementary disciplines VENTANA Benchmark Digital Slide Scanning & uPATH software NAVIFY® Tumor Board HE 600 ULTRA Advanced Image Analysis Preanalytics Tissue staining TISSUE WORKFLOW AVENIO Millisect MagNA Pure 24 PCR-based testing MOLECULAR Cell-free DNA coba
Slide 25: Molecular Diagnostics: Centralized and mPoC Solutions
Molecular Diagnostics: Centralized and mPoC Solutions Infectious Genomics & Donor Screening Sexual Health Transplant Microbiology mPoC Disease Oncology • Multiplex HIV, HCV, HBV • HIV • Human Papillomavirus • CMV • MTB/MAI/RIF-INH • BRAF • Influenza A/B • West Nile Virus • Hepatitis B, C • Chlamydia
Slide 26: cobas 6800/8800 Systems driving growth in molecular
cobas® 6800/8800 Systems driving growth in molecular Menu continues to expand to support consolidated testing Antimicrobial Donor Screening Infectious Disease Sexual Health Transplant Respiratory Stewardship MPX HIV-1 HPV CMV MTB MTB-RIF/INH WNV HBV CT/NG ADV MAI DPX HCV TV/MG MPLX Respiratory EBV (
Slide 27: Flu season driving cobas Liat System sales
Flu season driving cobas® Liat® System sales Pediatric and emergency room focus segments Launched globally with placement in every region cobas® Liat® cobas® Liat® Analyzer assay tube Instrument installed base: >4,000 • Only system that delivers RT-PCR results in under 20 mins at the point of care •
Slide 28: Tissue Diagnostics
About Roche Diagnostics Diagnostics Strategy and Business Model Financials Organization and Core Technologies – Tissue Diagnostics Personalized Healthcare and Data Management 28
Slide 29: Tissue Diagnostics: Product Portfolio
Tissue Diagnostics: Product Portfolio Comprehensive offering across the pathology workflow Pre-Analytical Primary Staining Advanced Staining Imaging/Reporting Tissue Preparation H&E Staining SS IHC ISH Image Analysis Work • Tracking • Primary Diagnosis • Quantitative analyses • Grossing • Tissue • R
Slide 30: Integrated Digital Pathology
Integrated Digital Pathology Transforming pathology with leading assays with actionable medical insights and recommedations PATHOLOGIST IMAGE SCANNING ANALYSIS WORKFLOW Roche Image Roche DP 200 Roche uPATH Analysis Algorithms* Deliver PRECISION DIAGNOSTICS by combining best- in-class advanced staini
Slide 31: Sequencing
About Roche Diagnostics Diagnostics Strategy and Business Model Financials Organization and Core Technologies – Sequencing Personalized Healthcare and Data Management 31
Slide 32: Roche Sequencing Solutions Vision
Roche Sequencing Solutions Vision Become the partner of choice for sequencing by making it simple and accessible enough for routine clinical use Sample preparation Sequencing Analytics & reporting Medical and Research Content Sample In Result Out Automated Workflow Scalable & Cost Effective Simplifi
Slide 33: Roche Sequencing Solutions
Roche Sequencing Solutions Innovating across the workflow to make NGS simple and accessible ANALYTICS MEDICAL & SAMPLE SEQUENCING AND REPORTING RESEARCH CONTENT PREPARATION AVENIO Millisect System Nanopore Sequencer* Software, bioinformatics NIPT: Harmony Prenatal Test (Tissue Dissection) and clinic
Slide 34: Launch of NGS Avenio tumor tissue analysis kits
Launch of NGS Avenio tumor tissue analysis kits1 Comprehensive genomic profiling of solid tumors AVENIO tumor tissue targeted kit Tumor • Pan-cancer assay for tumor profiling profiling • 17 genes (81 kb) • Includes all reagents & informatics for a “sample in – result out” solution • Each kit detects
Slide 35: Diabetes Care
About Roche Diagnostics Diagnostics Strategy and Business Model Financials Organization and Core Technologies – Diabetes Care Personalized Healthcare and Data Management 35
Slide 36: Roche Diabetes Care Portfolio
Roche Diabetes Care Portfolio Digital Diabetes Management Solutions RocheDiabetes Care Platform mySugr Accu-Chek SmartPix Accu-Chek Connect emminens Continuous Glucose Monitoring Blood Glucose Monitoring Senseonics Eversense XL Accu-Chek Guide Accu-Chek Instant Accu-Chek SugarView Accu-Chek Mobile I
Slide 37: Personalized Healthcare and Data Management
About Roche Diagnostics Diagnostics Strategy and Business Model Financials Organization and Core Technologies Personalized Healthcare and Data Management 37
Slide 38: Leader in Personalised Healthcare (PHC)
Roche Diagnostics Leader in Personalised Healthcare (PHC) • 60% of late stage Pharma development products have an accompanying companion diagnostics test • Combined strengths of Pharmaceuticals and Diagnostics: 300 internal collaboration, 50 external collaborations • Synergies in research, developme
Slide 39: Growing a portfolio of decision support solutions
Growing a portfolio of decision support solutions NAVIFY Portfolio and Platform Aggregated Data Insights1 Decision Support Apps (incl. AI): e.g. Literature Search, Clinical Trial Matching, Guidelines, Medical Algorithms Workflow Products: e.g. Tumor Board, Oncologist workflow, Lab Interpretation Sup
Slide 40: Expanding CDx Menu
Expanding CDx Menu Market leading portfolio Indication Biomarker Therapy HER2 Herceptin, Kadcyla, Perjeta Breast Cancer PIK3CA Piqray EGFR Gilotrif, Iressa, Tagrisso, Tarceva, ALK Alecensa, Xalkori, Zykadia Non-Small Cell Lung Cancer PD-L1 Imfinzi, Keytruda, Opdivo, Tecentriq BRAF Tafinlar in combin
Slide 41: Doing now what patients need next
Doing now what patients need next 41